Associations of HLA-A and HLA-B with vancomycin-induced drug reaction with eosinophilia and systemic symptoms in the Han-Chinese population

Vancomycin is a commonly used antibiotic; however, it can cause life-threatening severe cutaneous adverse reactions, such as drug reaction with eosinophilia and systemic symptoms (DRESS). A previous study has reported a strong association between HLA-A*32:01 and vancomycin-induced DRESS in European ethnicity. Herein, we aim to investigate the genetic predisposition of vancomycin-induced DRESS in the Han-Chinese population. In this study, we enrolled a total of 26 patients with vancomycin-induced DRESS, 1,616 general population controls, and 51 subjects tolerant to vancomycin. In vitro granulysin-based lymphocyte activation tests (LAT) were conducted among 6 vancomycin-induced DRESS patients who were concomitantly receiving other medicines. HLA-A and HLA-B genotypes were determined by sequencing-based typing. Our results found that vancomycin-induced DRESS was associated with HLA-A*32:01 [odds ratio (OR) = 7.8, 95% confidence interval (CI) = 1.7–35.8; p-value = 0.035], HLA-B*07:05 (OR = 32.3, 95% CI = 2.8–367.7; p-value = 0.047), HLA-B*40:06 (OR = 4.7, 95% CI = 1.3–16.1; p-value = 0.036) and HLA-B*67:01 (OR = 44.8, 95% CI = 7.2–280.4; p-value = 0.002) when comparing the vancomycin-induced DRESS patients with the general population controls. LAT results showed that granulysin significantly increased in the vancomycin-induced DRESS patients upon vancomycin stimulation (4.7 ± 3.7 fold increased), but not upon other co-medicines. This study identified that, in addition to HLA-A*32:01, HLA-B*07:05, HLA-B*40:06, and HLA-B*67:01 were also genetic markers for vancomycin-induced DRESS in the Han-Chinese population. Associations of ethnic variances in HLA with vancomycin-DRESS were observed.

[1]  W. Chung,et al.  An Updated Review of Genetic Associations With Severe Adverse Drug Reactions: Translation and Implementation of Pharmacogenomic Testing in Clinical Practice , 2022, Frontiers in Pharmacology.

[2]  W. Chung,et al.  Genetics of Severe Cutaneous Adverse Reactions , 2021, Frontiers in Medicine.

[3]  M. Pirmohamed,et al.  HLA-B*13 :01 Is a Predictive Marker of Dapsone-Induced Severe Cutaneous Adverse Reactions in Thai Patients , 2021, Frontiers in Immunology.

[4]  H. Asada,et al.  Current Perspective Regarding the Immunopathogenesis of Drug-Induced Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms (DIHS/DRESS) , 2021, International journal of molecular sciences.

[5]  W. Chung,et al.  Granulysin-based lymphocyte activation test for evaluating drug causality in antiepileptics-induced severe cutaneous adverse reactions. , 2020, The Journal of investigative dermatology.

[6]  Yen‐Hua Huang,et al.  Whole Genome Sequencing Identifies Genetic Variants Associated with Co-trimoxazole Hypersensitivity in Asians. , 2020, The Journal of allergy and clinical immunology.

[7]  L. French,et al.  Clinical and pathogenic aspects of the severe cutaneous adverse reaction epidermal necrolysis (EN) , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

[8]  R. Altman,et al.  Pharmacogenomics in Asian Subpopulations and Impacts on Commonly Prescribed Medications , 2020, Clinical and translational science.

[9]  Tina M. Willson,et al.  Epidemiology, disposition and treatment of ambulatory Veterans with skin and soft tissue infections. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  S. Mallal,et al.  Identification of drug-specific public TCR driving severe cutaneous adverse reactions , 2019, Nature Communications.

[11]  I. James,et al.  HLA-A*32:01 is strongly associated with vancomycin-induced drug reaction with eosinophilia and systemic symptoms. , 2019, The Journal of allergy and clinical immunology.

[12]  M. Schumacher,et al.  HLA‐B*57:01 confers genetic susceptibility to carbamazepine‐induced SJS/TEN in Europeans , 2019, Allergy.

[13]  Steven J. M. Jones,et al.  Whole-Genome Sequencing in Cancer. , 2018, Cold Spring Harbor perspectives in medicine.

[14]  I. Busmanis,et al.  Relapsing Course of Sulfasalazine-Induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Complicated by Alopecia Universalis and Vitiligo. , 2018, Annals of the Academy of Medicine, Singapore.

[15]  M. Benton,et al.  Next Generation Sequencing Methods for Diagnosis of Epilepsy Syndromes , 2018, Front. Genet..

[16]  W-W Chen,et al.  Delayed‐type hypersensitivity reactions induced by proton pump inhibitors: A clinical and in vitro T‐cell reactivity study , 2018, Allergy.

[17]  W. Chung,et al.  Pharmacogenomic Advances in the Prediction and Prevention of Cutaneous Idiosyncratic Drug Reactions , 2017, Clinical pharmacology and therapeutics.

[18]  M. Schumacher,et al.  Interleukin-15 Is Associated with Severity and Mortality in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. , 2017, The Journal of investigative dermatology.

[19]  A. Barbaud,et al.  Histopathological study of six types of adverse cutaneous drug reactions using granulysin expression , 2016, International journal of dermatology.

[20]  R. Hui,et al.  Impact of the HLA-B(*)58:01 Allele and Renal Impairment on Allopurinol-Induced Cutaneous Adverse Reactions. , 2016, The Journal of investigative dermatology.

[21]  W. Chung,et al.  Severe cutaneous adverse drug reactions , 2016, The Journal of dermatology.

[22]  M. Lee,et al.  Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study , 2015, BMJ : British Medical Journal.

[23]  Wei-Chi Wang,et al.  Oxypurinol-Specific T Cells Possess Preferential TCR Clonotypes and Express Granulysin in Allopurinol-Induced Severe Cutaneous Adverse Reactions. , 2015, The Journal of investigative dermatology.

[24]  Thachanan Kongpan,et al.  Candidate HLA genes for prediction of co-trimoxazole-induced severe cutaneous reactions , 2015, Pharmacogenetics and genomics.

[25]  Vance G. Fowler,et al.  Staphylococcus aureus Infections: Epidemiology, Pathophysiology, Clinical Manifestations, and Management , 2015, Clinical Microbiology Reviews.

[26]  Joseph J. Carreno,et al.  Vancomycin‐Associated Renal Dysfunction: Where Are We Now? , 2014, Pharmacotherapy.

[27]  S. Tsai,et al.  Genetic variants associated with phenytoin-related severe cutaneous adverse reactions. , 2014, JAMA.

[28]  E. Génin,et al.  HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis , 2013, The Pharmacogenomics Journal.

[29]  W. Pichler,et al.  Oxypurinol Directly and Immediately Activates the Drug-Specific T Cells via the Preferential Use of HLA-B*58:01 , 2014, The Journal of Immunology.

[30]  L. Naldi,et al.  Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study , 2013, The British journal of dermatology.

[31]  C. Largiadèr,et al.  Allopurinol hypersensitivity is primarily mediated by dose‐dependent oxypurinol‐specific T cell response , 2013, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[32]  P. D. de Bakker,et al.  HLA-B*13:01 and the dapsone hypersensitivity syndrome. , 2013, The New England journal of medicine.

[33]  Yi-Fang Cheng,et al.  A new nucleic acid-based agent inhibits cytotoxic T lymphocyte-mediated immune disorders. , 2013, The Journal of allergy and clinical immunology.

[34]  W. Tassaneeyakul,et al.  Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. , 2013, JAMA dermatology.

[35]  P. Kwan,et al.  HLA‐B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese , 2013, Epilepsia.

[36]  T. Shiohara,et al.  Short- and long-term outcomes of 34 patients with drug-induced hypersensitivity syndrome in a single institution. , 2013, Journal of the American Academy of Dermatology.

[37]  C. Chu,et al.  Long-term sequelae of drug reaction with eosinophilia and systemic symptoms: a retrospective cohort study from Taiwan. , 2013, Journal of the American Academy of Dermatology.

[38]  Yuhki Sato,et al.  Is Peak Concentration Needed in Therapeutic Drug Monitoring of Vancomycin? A Pharmacokinetic-Pharmacodynamic Analysis in Patients with Methicillin-Resistant Staphylococcus aureus Pneumonia , 2012, Chemotherapy.

[39]  M. Landrum,et al.  Epidemiology of Staphylococcus aureus blood and skin and soft tissue infections in the US military health system, 2005-2010. , 2012, JAMA.

[40]  K. Blumenthal,et al.  The importance of vancomycin in drug rash with eosinophilia and systemic symptoms (DRESS) syndrome. , 2012, Allergy and asthma proceedings.

[41]  J. Roujeau,et al.  The DRESS syndrome: a literature review. , 2011, The American journal of medicine.

[42]  J. Jung,et al.  Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans , 2011, Pharmacogenetics and genomics.

[43]  Chen-Yang Shen,et al.  Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. , 2011, The New England journal of medicine.

[44]  C. Chu,et al.  Drug reaction with eosinophilia and systemic symptoms: a retrospective study of 60 cases. , 2010, Archives of dermatology.

[45]  A. Dunant,et al.  ALDEN, an Algorithm for Assessment of Drug Causality in Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: Comparison With Case–Control Analysis , 2010, Clinical pharmacology and therapeutics.

[46]  S. Tiamkao,et al.  Association between HLA‐B*1502 and carbamazepine‐induced severe cutaneous adverse drug reactions in a Thai population , 2010, Epilepsia.

[47]  S. Tiamkao,et al.  Strong association between HLA-B*5801 and allopurinol-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in a Thai population , 2009, Pharmacogenetics and genomics.

[48]  K. Suphapeetiporn,et al.  Carbamazepine and phenytoin induced Stevens‐Johnson syndrome is associated with HLA‐B*1502 allele in Thai population , 2008, Epilepsia.

[49]  Yuan-Tsong Chen,et al.  Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis , 2008, Nature Medicine.

[50]  C. Sotozono,et al.  HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. , 2008, Pharmacogenomics.

[51]  T. Kuo,et al.  Clinicopathlogical features and prognosis of drug rash with eosinophilia and systemic symptoms: a study of 30 cases in Taiwan , 2008, Journal of the European Academy of Dermatology and Venereology : JEADV.

[52]  M. Assal,et al.  Vancomycin-Induced DRESS Syndrome in a Female Patient , 2008, Pharmacology.

[53]  S. Mallal,et al.  HLA-B*5701 screening for hypersensitivity to abacavir. , 2008, The New England journal of medicine.

[54]  L. Naldi,et al.  A European study of HLA-B in Stevens–Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs , 2008, Pharmacogenetics and genomics.

[55]  M. Tohyama,et al.  Association of human herpesvirus 6 reactivation with the flaring and severity of drug‐induced hypersensitivity syndrome , 2007, The British journal of dermatology.

[56]  R. Tamagawa‐Mineoka,et al.  DRESS syndrome caused by teicoplanin and vancomycin, associated with reactivation of human herpesvirus‐6 , 2007, International journal of dermatology.

[57]  Sang-Heon Cho,et al.  A Case of Hypersensitivity Syndrome to Both Vancomycin and Teicoplanin , 2006, Journal of Korean medical science.

[58]  Yuan-Tsong Chen,et al.  HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[59]  Yuan-Tsong Chen,et al.  A marker for Stevens–Johnson syndrome , 2004 .

[60]  D. Hepner,et al.  Anaphylaxis During the Perioperative Period , 2003, Anesthesia and analgesia.

[61]  G. Drusano,et al.  Prospective Evaluation of the Effect of an Aminoglycoside Dosing Regimen on Rates of Observed Nephrotoxicity and Ototoxicity , 1999, Antimicrobial Agents and Chemotherapy.

[62]  R. Stern,et al.  Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. , 1993, Archives of dermatology.

[63]  H. Leaver,et al.  Anaphylactoid reactions to vancomycin during anaesthesia: two clinical reports , 1985, Canadian Anaesthetists' Society journal.

[64]  D. Greenblatt,et al.  A method for estimating the probability of adverse drug reactions , 1981, Clinical pharmacology and therapeutics.